← Leaderboards
Gerald Francis Vovis
Helix Therapeutics, Llc
$2,728,489
Attributed
$2,728,489
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2008–24$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,728,489 · 3
By mechanism
R44$2,400,000 · 1
R43$328,489 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Mouse Model”
- Dennis R. Burton · Scripps Research Institute$280,661,242
- David Heimbrook · Leidos Biomedical Research, Inc.$84,491,283
- Kc Kent Lloyd · University Of California At Davis$74,285,556
- Alan F Horwitz · University Of Virginia Charlottesville$73,668,592
- Stanley B Prusiner · University Of California San Francisco$61,905,394
- Ed Lein · Allen Institute$59,425,748
Research focus
Mouse ModelCellsMutationDna RepairDrug ResistanceLeadGenomeResistanceCell LineSuccessSeriesAlkylating AgentsApoptosisDna LesionAnalogDna-Directed Dna PolymeraseDoseDemethylationAchievementBiological MarkersColon CarcinomaDefectCollectionAdenine
Grant awards (5)
Development of Targeted Damaging Agents for the Treatment of Drug-Resistant Gliomas$892,099
R44 · FY2024 · CA · contact PI
Development of Targeted Damaging Agents for the Treatment of Drug-Resistant Gliomas$1,107,901
R44 · FY2023 · CA · contact PI
Development of Targeted Damaging Agents for the Treatment of Drug-Resistant Gliomas$400,000
R44 · FY2022 · CA · contact PI
Beta-Globin Gene Correction Using Peptide Nucleic Acids for the Treatment of Sick$228,490
R43 · FY2010 · HL · contact PI
Targeted CCR5 Gene Inactivation Using Peptide Nucleic Acids$99,999
R43 · FY2008 · AI · contact PI